01 1Shilpa Medicare
01 1LENVATINIB MESYLATE
01 1India
01 1Active
01 1Complete
GDUFA
DMF Review : Complete
Rev. Date : 2018-11-20
Pay. Date : 2018-09-04
DMF Number : 33083
Submission : 2018-09-04
Status : Active
Type : II
20
Shilpa Pharma Lifesciences Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is LENVATINIB MESYLATE, with a corresponding US DMF Number 33083.
Remarkably, this DMF maintains an Active status since its submission on September 04, 2018, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of November 20, 2018, and payment made on September 04, 2018, indicating their dedication to facilitating drug approvals, Categorized as Type II
